A

Mice Humans Animals Female Radiopharmaceuticals / therapeutic use Receptors, Metabotropic Glutamate / genetics Breast Neoplasms / genetics Melanoma
(211)At-AITM alpha-emitting radiopharmaceutical glutamine metabolism metabotropic glutamate receptor 1 oncoprotein pan-cancer reprogrammed senescence-associated secretory phenotype senescence targeted alpha radiopharmaceutical therapy α−particle

Journal

Cell reports. Medicine
ISSN: 2666-3791
Titre abrégé: Cell Rep Med
Pays: United States
ID NLM: 101766894

Informations de publication

Date de publication:
18 04 2023
Historique:
received: 21 09 2022
revised: 01 11 2022
accepted: 09 02 2023
medline: 21 4 2023
pubmed: 2 4 2023
entrez: 1 4 2023
Statut: ppublish

Résumé

Metabotropic glutamate receptor 1 (mGluR1), a key mediator of glutamatergic signaling, is frequently overexpressed in tumor cells and is an attractive drug target for most cancers. Here, we present a targeted radiopharmaceutical therapy strategy that antagonistically recognizes mGluR1 and eradicates mGluR1

Identifiants

DOI: 10.1016/j.xcrm.2023.100960 PMID: 37003259 PMC: PMC10140459
pubmed: 37003259
pii: S2666-3791(23)00052-6
doi: 10.1016/j.xcrm.2023.100960
pmc: PMC10140459
pii:
doi:

Substances chimiques

metabotropic glutamate receptor type 1 0
Radiopharmaceuticals 0
Receptors, Metabotropic Glutamate 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

100960

Informations de copyright

Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests The authors declare no competing interests.

Références

Science. 2014 Apr 4;344(6179):58-64
pubmed: 24603153
Cancer Res. 2019 Apr 15;79(8):1799-1809
pubmed: 30987979
Cell Metab. 2008 Jan;7(1):11-20
pubmed: 18177721
Eur J Med Res. 2022 Jul 2;27(1):107
pubmed: 35780243
Clin Cancer Res. 2012 Aug 15;18(16):4240-6
pubmed: 22648273
J Clin Invest. 2013 Sep;123(9):3678-84
pubmed: 23999442
Trends Pharmacol Sci. 2009 Aug;30(8):431-40
pubmed: 19616318
Cancer Discov. 2022 Jan;12(1):31-46
pubmed: 35022204
Front Oncol. 2022 May 23;12:863266
pubmed: 35677150
Mol Cancer Ther. 2022 Apr 1;21(4):667-676
pubmed: 35086953
N Engl J Med. 2013 Jul 18;369(3):213-23
pubmed: 23863050
Clin Cancer Res. 2020 Dec 1;26(23):6230-6241
pubmed: 32933998
Cell Signal. 2006 Aug;18(8):1279-86
pubmed: 16305822
J Nucl Med. 1980 Jul;21(7):670-5
pubmed: 7391842
Int J Cancer. 2014 Oct 15;135(8):1852-9
pubmed: 24643962
J Nucl Med. 2020 Feb;61(2):242-248
pubmed: 31451486
Bioorg Med Chem Lett. 2009 Sep 15;19(18):5464-8
pubmed: 19674894
Proc Natl Acad Sci U S A. 2011 Sep 13;108(37):15219-24
pubmed: 21896768
Neuropharmacology. 2017 Mar 15;115:193-202
pubmed: 26896755
Annu Rev Pharmacol Toxicol. 2010;50:295-322
pubmed: 20055706
Mol Imaging Biol. 2003 Nov-Dec;5(6):376-89
pubmed: 14667492
J Nucl Med. 1996 Mar;37(3):538-46
pubmed: 8772664
Pigment Cell Melanoma Res. 2015 Jan;28(1):105-9
pubmed: 25363352
Nat Rev Drug Discov. 2020 Sep;19(9):589-608
pubmed: 32728208
Clin Cancer Res. 2022 Sep 15;28(18):4146-4157
pubmed: 35861867
Cancer Res. 2019 Nov 1;79(21):5479-5481
pubmed: 31676677
Nat Genet. 2003 May;34(1):108-12
pubmed: 12704387
Cancer Res. 2014 May 1;74(9):2499-509
pubmed: 24491800
Int J Radiat Oncol Biol Phys. 1991 May 15;21(1):109-22
pubmed: 2032882
Cell Biochem Funct. 2003 Mar;21(1):1-9
pubmed: 12579515
Cancer Sci. 2022 Feb;113(2):721-732
pubmed: 34935247
Breast Cancer Res Treat. 2015 May;151(1):57-73
pubmed: 25859923
Nat Cell Biol. 2015 Sep;17(9):1205-17
pubmed: 26280535
Cancer Res. 2010 May 15;70(10):4045-53
pubmed: 20442292
Cancer Metastasis Rev. 2004 Aug-Dec;23(3-4):237-57
pubmed: 15197326
Eur J Pharmacol. 2016 Jul 15;783:103-11
pubmed: 27132814
J Nucl Med. 2018 Sep;59(9):1340-1349
pubmed: 30042161
Pigment Cell Melanoma Res. 2018 Jul;31(4):534-540
pubmed: 29453787
Nat Genet. 2014 May;46(5):474-7
pubmed: 24658000
Cell Death Differ. 2008 Jul;15(7):1153-62
pubmed: 18404154
Breast Cancer Res Treat. 2012 Apr;132(2):565-73
pubmed: 21681448
J Invest Dermatol. 2010 Sep;130(9):2240-9
pubmed: 20505744
J Nucl Med. 1982 Dec;23(12):1133-7
pubmed: 6982967
J Immunother Cancer. 2021 Jan;9(1):
pubmed: 33408092
Mol Metab. 2022 May;59:101466
pubmed: 35219875
J Nucl Med. 2010 Feb;51(2):311-28
pubmed: 20080889
Clin Cancer Res. 2009 Jun 1;15(11):3896-902
pubmed: 19458050
Cancer Biother Radiopharm. 2013 Nov;28(9):657-64
pubmed: 23789969
Genes Dev. 2009 Mar 1;23(5):537-48
pubmed: 19270154
J Med Chem. 2015 Feb 12;58(3):1513-23
pubmed: 25602363
J Nucl Med. 2021 May 10;62(5):669-674
pubmed: 33008928
Q J Nucl Med Mol Imaging. 2004 Dec;48(4):289-96
pubmed: 15640792

Auteurs

Lin Xie (L)

Department of Advanced Nuclear Medicine Sciences, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba 263-8555, Japan. Electronic address: xie.lin@qst.go.jp.

Lulu Zhang (L)

Department of Advanced Nuclear Medicine Sciences, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba 263-8555, Japan; Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing 211166, China.

Kuan Hu (K)

Department of Advanced Nuclear Medicine Sciences, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba 263-8555, Japan; State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China.

Masayuki Hanyu (M)

Department of Advanced Nuclear Medicine Sciences, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba 263-8555, Japan.

Yiding Zhang (Y)

Department of Advanced Nuclear Medicine Sciences, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba 263-8555, Japan.

Masayuki Fujinaga (M)

Department of Advanced Nuclear Medicine Sciences, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba 263-8555, Japan.

Katsuyuki Minegishi (K)

Department of Advanced Nuclear Medicine Sciences, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba 263-8555, Japan.

Takayuki Ohkubo (T)

Department of Advanced Nuclear Medicine Sciences, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba 263-8555, Japan.

Kotaro Nagatsu (K)

Department of Advanced Nuclear Medicine Sciences, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba 263-8555, Japan.

Cuiping Jiang (C)

Department of Advanced Nuclear Medicine Sciences, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba 263-8555, Japan; Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing 211166, China.

Takashi Shimokawa (T)

Department of Charged Particle Therapy Research, Quantum Life and Medical Science, National Institutes for Quantum Science and Technology, Chiba 263-8555, Japan.

Kazuma Ashisuke (K)

Department of Charged Particle Therapy Research, Quantum Life and Medical Science, National Institutes for Quantum Science and Technology, Chiba 263-8555, Japan.

Noriyuki Okonogi (N)

Department of Charged Particle Therapy Research, Quantum Life and Medical Science, National Institutes for Quantum Science and Technology, Chiba 263-8555, Japan.

Shigeru Yamada (S)

Department of Charged Particle Therapy Research, Quantum Life and Medical Science, National Institutes for Quantum Science and Technology, Chiba 263-8555, Japan.

Feng Wang (F)

Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing 211166, China.

Rui Wang (R)

State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China.

Ming-Rong Zhang (MR)

Department of Advanced Nuclear Medicine Sciences, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba 263-8555, Japan. Electronic address: zhang.ming-rong@qst.go.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › A
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › A
questionsmedicales.fr › Eucaryotes › Animaux › A
questionsmedicales.fr › Actions chimiques et utilisations › Utilisations spécialisées de produits chimiques › Produits chimiques de laboratoire › Indicateurs et réactifs › Radiopharmaceutiques › A
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs aux neuromédiateurs › Récepteurs aux acides aminés › Récepteurs au glutamate › Récepteurs métabotropes au glutamate › A
questionsmedicales.fr › Maladies de la peau et du tissu conjonctif › Maladies de la peau › Maladies du sein › Tumeurs du sein › A
questionsmedicales.fr › Tumeurs › Tumeurs par type histologique › Naevus et mélanomes › Mélanome › A